As of 06 Nov 2026 13:05 UTC. Status is always as stated in the latest recorded notice; the sources do not publish resolution, so nothing on this page says a medicine is back — see methodology.
Presentations, as stated in the latest recorded notice
Each line is re-expressed from MSN/2024/069 (05 Jun 2024): the product named, the status the source stated, and the expected-back phrase kept as written. Not the source's sentence, and not an observation of stock.
| Presentation | Status, as stated | Expected back, as stated | Stated in |
|---|---|---|---|
| Imiquimod (Aldara®) 5% creamaffected product · inferred from phrasing | Out of stock, as stated | late July 2024precision: late in the month · window end 31 Jul 2024, derived from “late July 2024” | notice of 05 Jun 2024 |
| Podophyllotoxin (Warticon®) 0.5% solutionaffected product · inferred from phrasing | Out of stock, as stated | mid-June 2024precision: mid-month · window end 20 Jun 2024, derived from “mid-June 2024” | notice of 05 Jun 2024 |
| Podophyllotoxin (Warticon®) 0.15% creamaffected product · inferred from phrasing | Out of stock, as stated | mid-October 2024precision: mid-month · window end 20 Oct 2024, derived from “mid-October 2024” | notice of 05 Jun 2024 |
| Imiquimod (Zyclara®) 3.75% creamnamed by the source as remaining available · inferred from phrasing | Stated as available; can support only a partial uplift | — not stated for this line | notice of 05 Jun 2024 |
| Imiquimod (Bascellex®) 50 mg/g creamnamed by the source as remaining available · inferred from phrasing | Stated as available; can support only a partial uplift | — not stated for this line | notice of 05 Jun 2024 |
| Fluorouracil (Efudix®) 5% creamnamed by the source as remaining available · inferred from phrasing | Stated as available; cannot support an uplift in demand | — not stated for this line | notice of 05 Jun 2024 |
| Diclofenac (Solaraze®) 3% gel, fluorouracil with salicylic acid (Actikerall®) cutaneous solution and tirbanibulin (Klisyri®) ointmentnamed by the source as remaining available · inferred from phrasing · its own page → | Stated as available | — not stated for this line | notice of 05 Jun 2024 |
| Camellia sinensis (Catephen®) 10% ointmentnamed by the source as remaining available · inferred from phrasing | Stated as available; can support only a partial uplift | — not stated for this line | notice of 05 Jun 2024 |
Protocol in force
No Serious Shortage Protocol matched to this name is in force on the NHSBSA register. Matching is by name until identifier coding lands.
Named in the source as remaining available
- Imiquimod (Zyclara®) 3.75% cream — named by the source as remaining available (inferred from phrasing)
- Imiquimod (Bascellex®) 50 mg/g cream — named by the source as remaining available (inferred from phrasing)
- Fluorouracil (Efudix®) 5% cream — named by the source as remaining available (inferred from phrasing)
- Diclofenac (Solaraze®) 3% gel, fluorouracil with salicylic acid (Actikerall®) cutaneous solution and tirbanibulin (Klisyri®) ointment — named by the source as remaining available (inferred from phrasing)
- Camellia sinensis (Catephen®) 10% ointment — named by the source as remaining available (inferred from phrasing)
Only names the source itself listed, as it listed them (source post ↗). No substitution, dosing or counselling advice is given here or implied.
Identifiers — Imiquimod
BNF chemical and SNOMED identifiers from NHSBSA Prescription Cost Analysis (Open Government Licence), matched by name (presentation name), confidence 0.90 — grouping under review where marked Release Jul 2026.
BNF SNOMED mapping, NHSBSA Copyright 2026; Prescription Cost Analysis (PCA) Monthly Administrative Data, NHSBSA Copyright 2026. This information is licenced under the terms of the Open Government Licence.
History
Notified short 2 times on record since 2023 — a recurring shortage spanning 1.3 years. We record when a shortage is declared, not when stock returns — the source doesn't publish that. An update sharing a reference counts as one episode.
| Issued | Notice | Kind | Tier | Reference |
|---|---|---|---|---|
| 05 Jun 2024 | Medicine Supply Notification: Imiquimod (Aldara® ) 5% cream and podophyllotoxin (Warticon® ) 0.5% solution and 0.15% cream | Supply notification | Tier 2 | MSN/2024/069 |
| 03 Feb 2023 | Medicine Supply Notification: Imiquimod (Aldara® 5% and Bascellex® 50mg/g) cream | Supply notification | Tier 2 | MSN/2023/010 |
Also recorded under
Bracketed names seen in this medicine's notice titles: aldara. Grouping is by the head name in each title; brand and generic names may still sit on separate pages until identifier coding refines it — see the A–Z.
Scotland — separate record
NHS Scotland issues its own Medicine Supply Alert Notices. These match this medicine's name; they are shown beside, never added to, the England record.
- MSAN(2024)66 Imiquimod (Aldara® 5% and Bascellex® 50mg/g) cream 250mg sachets · issued 11 Dec 2024 · valid until mid-January 2025, as stated · matched by name PDF ↗
- MSAN(2024)34 Imiquimod (Aldara®) 5% cream and podophyllotoxin (Warticon®) 0.5% solution · issued 11 Jun 2024 · valid until mid-October 2024, as stated · matched by name PDF ↗